Date: 2013-10-30
Type of information: Production agreement
Compound: OPT-302 (soluble form of human VEGFR-3)
Company: Royal DSM (The Netherlands) Opthea (Australia)
Therapeutic area: Ophtalmological diseases
Type agreement: development
manufacturing
production
Action mechanism: VGX-300 is a soluble receptor consisting of the first three extracellular domains of human VEGFR-3 linked to the Fc region of human IgG1. OPT-302 is a derivative of VGX-300 which has been optimised for local ocular administration. This candidate specifically blocks VEGF-C and VEGF-D from binding and activating VEGFR-2 and VEGFR-3.
Disease: wet (neovascular) age-related macular degeneration (wet AMD)
Details: * On October 30, 2013, DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has announced that it has signed an agreement with Opthea Pty Ltd of Melbourne, Australia. The contract covers process development and cGMP manufacture by DSM for Opthea\'s lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel formation and are involved in the progression of eye diseases. This project represents an agreement for process development at DSM Biologics’ Groningen facility and manufacture at the newly established cGMP facility in Brisbane, Australia. Opthea, a private 100% owned subsidiary of Circadian Technologies, is developing its lead molecule OPT-302, previously known as VGX-300, initially for the treatment of “wet” (neovascular) age-related macular degeneration (wet AMD).
Financial terms: Financial terms were not disclosed.
Latest news:
